Swiss National Bank Acquires 400 Shares of Regeneron Pharmaceuticals Inc (REGN)

Swiss National Bank lifted its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 288,900 shares of the biopharmaceutical company’s stock after acquiring an additional 400 shares during the quarter. Swiss National Bank owned approximately 0.27% of Regeneron Pharmaceuticals worth $108,615,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. California Public Employees Retirement System increased its position in shares of Regeneron Pharmaceuticals by 6.3% in the fourth quarter. California Public Employees Retirement System now owns 184,939 shares of the biopharmaceutical company’s stock valued at $69,530,000 after acquiring an additional 10,910 shares during the last quarter. AE Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $206,000. BT Investment Management Ltd increased its position in Regeneron Pharmaceuticals by 6,246.3% during the fourth quarter. BT Investment Management Ltd now owns 9,456 shares of the biopharmaceutical company’s stock worth $3,555,000 after buying an additional 9,307 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 14,278 shares of the biopharmaceutical company’s stock worth $5,622,000 after buying an additional 450 shares during the last quarter. Finally, Loeb Partners Corp acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $564,000. 64.67% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 10.80% of the stock is owned by corporate insiders.

REGN has been the topic of a number of recent analyst reports. BTIG Research reissued a “buy” rating and set a $520.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, November 22nd. Citigroup restated a “buy” rating and set a $480.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, November 9th. Guggenheim restated a “buy” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Piper Jaffray Companies restated a “buy” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, November 13th. Finally, Argus cut their price target on Regeneron Pharmaceuticals from $540.00 to $470.00 and set a “buy” rating for the company in a research note on Thursday, December 28th. Three analysts have rated the stock with a sell rating, fourteen have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $457.03.

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) traded down $1.03 on Monday, reaching $332.15. 1,175,400 shares of the company’s stock were exchanged, compared to its average volume of 1,095,561. The company has a quick ratio of 3.18, a current ratio of 3.82 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $35,771.23, a PE ratio of 32.19, a P/E/G ratio of 1.04 and a beta of 1.47. Regeneron Pharmaceuticals Inc has a twelve month low of $313.53 and a twelve month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.18 by $1.05. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The business’s revenue was up 28.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.04 EPS. research analysts forecast that Regeneron Pharmaceuticals Inc will post 19.2 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://stocknewstimes.com/2018/02/19/swiss-national-bank-acquires-400-shares-of-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply